Largest pharmaceuticals by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 61 pharmaceuticals ranked by total liabilities, at NOK 1.33T, ahead of Pfizer (NOK 1.18T) and Johnson & Johnson (NOK 1.14T). Figures as of 18 Nov 2026, 14:39 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 61
- First
- AbbVieNOK 1.33T
- Median
- NOK 20.2B
- Combined market value
- NOK 49.85T
- Countries
- 10
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | NOK 1.33T | NOK 4.99T | NOK 2,825.68 | 0.42% down | 26% up | ||
| 2 | PfizerPFE · Health Care | NOK 1.18T | NOK 1.57T | NOK 275.80 | 0.02% up | 14% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | NOK 1.14T | NOK 6.49T | NOK 2,697.29 | 0.16% down | 38% up | ||
| 4 | Eli LillyLLY · Health Care | NOK 832.7B | NOK 12.23T | NOK 13,727.92 | 0.10% up | 35% up | ||
| 5 | Merck & CoMRK · Health Care | NOK 815.9B | NOK 3.36T | NOK 1,362.41 | 1.95% down | 51% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | NOK 693.1B | NOK 1.21T | NOK 590.37 | 0.73% down | 34% up | ||
| 7 | AstraZenecaAZN · Health Care | NOK 633.2B | NOK 2.72T | NOK 1,752.54 | 0.74% down | 2% up | ||
| 8 | NovartisNVS · Health Care | NOK 624B | NOK 2.88T | NOK 1,526.64 | 1.01% down | 25% up | ||
| 9 | SanofiSNY · Health Care | NOK 592.3B | NOK 1.11T | NOK 460.72 | 0.04% up | 4% down | ||
| 10 | GSKGSK · Health Care | NOK 580.8B | NOK 955.9B | NOK 476.90 | 0.01% down | 6% up | ||
| 11 | Novo NordiskNVO · Health Care | NOK 501.6B | NOK 1.72T | NOK 391.01 | 0.86% down | 17% down | ||
| 12 | Takeda PharmaceuticalTAK · Health Care | NOK 490.4B | NOK 666.3B | NOK 208.56 | 0.55% down | 54% up | ||
| 13 | Abbott LaboratoriesABT · Health Care | NOK 328.9B | NOK 1.76T | NOK 1,014.51 | 0.05% down | 17% down | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | NOK 318.1B | NOK 484B | NOK 414.79 | 0.47% up | 74% up | ||
| 15 | ViatrisVTRS · Health Care | NOK 217.8B | NOK 228.8B | NOK 199.55 | 0.71% up | 96% up | ||
| 16 | GrifolsGRFS · Health Care | NOK 130.2B | NOK 56.9B | NOK 83.62 | 0.00% | 1% up | ||
| 17 | ZoetisZTS · Health Care | NOK 117.6B | NOK 331B | NOK 814.58 | 0.71% up | 29% down | ||
| 18 | Royalty PharmaRPRX · Health Care | NOK 96B | NOK 383.5B | NOK 667.01 | 0.23% up | 78% up | ||
| 19 | Regeneron PharmaceuticalsREGN · Health Care | NOK 90.1B | NOK 967.1B | NOK 9,348.87 | 0.74% up | 36% up | ||
| 20 | Jazz PharmaceuticalsJAZZ · Health Care | NOK 71.1B | NOK 149.4B | NOK 2,328.18 | 0.18% down | 37% up | ||
| 21 | GenmabGMAB · Health Care | NOK 68.1B | NOK 310.2B | NOK 503.16 | 0.06% down | 70% up | ||
| 22 | Vertex PharmaceuticalsVRTX · Health Care | NOK 67.6B | NOK 1.32T | NOK 5,187.62 | 0.22% up | 27% up | ||
| 23 | Elanco Animal HealthELAN · Health Care | NOK 66B | NOK 127.9B | NOK 255.89 | 2.17% up | 20% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | NOK 40.5B | NOK 203B | NOK 1,515.50 | 0.06% down | 66% down | ||
| 25 | BeOne MedicinesONC · Health Care | NOK 37.1B | NOK 453.4B | NOK 3,969.30 | 0.87% down | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | NOK 35.6B | NOK 72.3B | NOK 207.42 | 1.36% up | 83% up | ||
| 27 | PTC TherapeuticsPTCT · Health Care | NOK 30.1B | NOK 48.8B | NOK 583.54 | 0.22% down | 20% down | ||
| 28 | Ionis PharmaceuticalsIONS · Health Care | NOK 29.4B | NOK 44.4B | NOK 266.45 | 2.00% up | 64% down | ||
| 29 | BridgeBio PharmaBBIO · Health Care | NOK 29.2B | NOK 145.4B | NOK 746.27 | 0.29% up | 17% up | ||
| 30 | Dr. Reddy's LaboratoriesRDY · Health Care | NOK 20.5B | NOK 120.7B | NOK 144.76 | 0.95% up | 5% up | ||
| 31 | CytokineticsCYTK · Health Care | NOK 20.2B | NOK 70.3B | NOK 504.37 | 0.78% up | 20% down | ||
| 32 | Ascendis PharmaASND · Health Care | NOK 15.8B | NOK 172.3B | NOK 2,626.17 | 0.06% down | 28% up | ||
| 33 | InsmedINSM · Health Care | NOK 14.8B | NOK 259.5B | NOK 1,182.86 | 0.18% up | 40% down | ||
| 34 | BioMarin PharmaceuticalBMRN · Health Care | NOK 14.6B | NOK 110.7B | NOK 571.47 | 0.80% up | 11% up | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | NOK 8.5B | NOK 59B | NOK 417.46 | 0.22% up | 10% up | ||
| 36 | United TherapeuticsUTHR · Health Care | NOK 7.6B | NOK 241.1B | NOK 5,660.99 | 0.03% up | 23% up | ||
| 37 | Legend BiotechLEGN · Health Care | NOK 7.1B | NOK 31.6B | NOK 162.68 | 4.22% up | 42% down | ||
| 38 | AlkermesALKS · Health Care | NOK 6.5B | NOK 75.2B | NOK 447.59 | 1.64% up | 58% up | ||
| 39 | Madrigal PharmaceuticalsMDGL · Health Care | NOK 6.4B | NOK 94.6B | NOK 4,074.14 | 0.36% down | 24% down | ||
| 40 | Axsome TherapeuticsAXSM · Health Care | NOK 5.8B | NOK 69.6B | NOK 1,323.75 | 0.49% up | 7% down | ||
| 41 | Ligand PharmaceuticalsLGND · Health Care | NOK 5.3B | NOK 57.6B | NOK 2,880.32 | 1.18% up | 43% up | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | NOK 5.1B | NOK 57.9B | NOK 886.86 | 0.46% down | 31% up | ||
| 43 | Travere TherapeuticsTVTX · Health Care | NOK 4.8B | NOK 47.4B | NOK 493.96 | 0.23% down | 44% up | ||
| 44 | Roivant SciencesROIV · Health Care | NOK 4B | NOK 272.8B | NOK 376.50 | 0.38% up | 90% up | ||
| 45 | TG TherapeuticsTGTX · Health Care | NOK 4B | NOK 93B | NOK 615.01 | 1.22% up | 107% up | ||
| 46 | Cogent BiosciencesCOGT · Health Care | NOK 2.9B | NOK 47.7B | NOK 274.11 | 1.58% up | 20% down | ||
| 47 | Rhythm PharmaceuticalsRYTM · Health Care | NOK 2B | NOK 77.9B | NOK 1,123.08 | 0.60% down | 13% up | ||
| 48 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | NOK 1.9B | NOK 73.3B | NOK 933.52 | 1.30% up | 126% up | ||
| 49 | Corcept TherapeuticsCORT · Health Care | NOK 1.8B | NOK 74.9B | NOK 684.59 | 0.83% up | 8% down | ||
| 50 | ABIVAXABVX · Health Care | NOK 1.4B | NOK 70.5B | NOK 805.76 | 1.29% up | 27% down | ||
| 51 | Definium TherapeuticsDFTX · Health Care | NOK 1B | NOK 39.1B | NOK 285.54 | 0.31% up | 169% up | ||
| 52 | Summit TherapeuticsSMMT · Health Care | NOK 894.5M | NOK 81.8B | NOK 102.27 | 1.08% down | 36% down | ||
| 53 | ErascaERAS · Health Care | NOK 687.8M | NOK 47B | NOK 133.81 | 0.58% down | 403% up | ||
| 54 | Spyre TherapeuticsSYRE · Health Care | NOK 606M | NOK 87.3B | NOK 919.46 | 1.16% up | 286% up | ||
| 55 | Praxis Precision MedicinesPRAX · Health Care | NOK 579.1M | NOK 82.7B | NOK 2,957.45 | 0.06% up | 61% up | ||
| 56 | Protagonist TherapeuticsPTGX · Health Care | NOK 518.2M | NOK 79.7B | NOK 1,220.36 | 1.03% up | 46% up | ||
| 57 | Dianthus TherapeuticsDNTH · Health Care | NOK 363.6M | NOK 47.6B | NOK 845.77 | 0.36% up | 113% up | ||
| 58 | Edgewise TherapeuticsEWTX · Health Care | NOK 294M | NOK 44.8B | NOK 409.23 | 0.46% up | 88% up | ||
| 59 | Oruka TherapeuticsORKA · Health Care | NOK 161.7M | NOK 64.9B | NOK 956.76 | 2.52% up | 241% up | ||
| 60 | Belite BioBLTE · Health Care | NOK 97.6M | NOK 62.1B | NOK 1,528.19 | 0.00% | 31% up | ||
| 61 | VeradermicsMANE · Health Care | NOK 88.7M | NOK 51.7B | NOK 1,225.35 | 0.46% up | 233% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6892 NOK).
Questions and answers
Which pharmaceuticals rank first by total liabilities?
AbbVie (NOK 1.33T), Pfizer (NOK 1.18T) and Johnson & Johnson (NOK 1.14T) are the top three of the 61 pharmaceuticals ranked by total liabilities as of 18 Nov 2026, 14:39 UTC.
How many pharmaceuticals are in this ranking?
61 are ranked by total liabilities.
What are these pharmaceuticals worth together?
The 61 pharmaceuticals ranked by total liabilities have a combined market value of NOK 49.85T as of 18 Nov 2026, 14:39 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.